Company research / ADAPY
Adaptimmune Therapeutics PLC (ADAPY)
- Sector Manufacturing
- Fiscal year ends around Dec 31
Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
For the year ended 2024-12-31, Adaptimmune Therapeutics PLC reported revenue of $178.03M. Revenue grew 195.3% from the prior annual period.
Key ratios (year ended 2024-12-31)
-38.6%
Operating margin
-39.8%
Net margin
-597.6%
Return on year-end equity
195.3%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.